Dale J Lange

Mount Sinai School Of Medicine Of Nyu

$70,720

Attributed

$70,720

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $24.5K · FY2005–09

$25K$18.8K$12.5K$6.3K$0

'05

'06

'07

'08

'09

Funding mix

By agency

NIH$70,720 · 7

By mechanism

M01$70,720 · 7

Top collaborators

No co-investigators on record.

Most similar at Mount Sinai School Of Medicine Of Nyu

Same institution · by research overlap

Others in their field

Top investigators on “Safety”

David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
Mitchell J Malone · Texas A&M Research Foundation$329,191,208
Gary D Acton · University Of California-Davis$320,373,312
Melynda Holmes · Technical Resources Inc$232,659,786
Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316

Research focus

SafetyDoseComputer Retrieval Of Information On Scientific Projects DatabaseResourcesPharmaceutical PreparationsResearch PersonnelUnited States National Institutes Of HealthGrantSourceFundingInstitutionNeurodegenerative DisordersCerebrospinal FluidAmyotrophic Lateral SclerosisMutationLymphocyteCodeGenesPyrimethamineEnzymesProteinsProtein ExpressionCellsMarketing

Grant awards (7)

USE OF PYRIMETHAMINE IN FAMILIAL ALS$22,265

M01 · FY2009 · RR · contact PI

MYOZYME TEMPORARY ACCESS PROGRAM$1,468

M01 · FY2009 · RR · contact PI

SAFETY AND TOLERABILITY OF PYRIMETHAMINE IN SPORADIC ALS$734

M01 · FY2009 · RR · contact PI

USE OF PYRIMETHAMINE IN FAMILIAL ALS$24,541

M01 · FY2008 · RR · contact PI

USE OF PYRIMETHAMINE IN FAMILIAL ALS$6,078

M01 · FY2007 · RR · contact PI

DISULFIRAM TREATMENT IN AMYOTROPHIC LATERAL SCLEROSIS$536

M01 · FY2006 · RR · contact PI

DISULFIRAM TREATMENT IN AMYOTROPHIC LATERAL SCLEROSIS$15,098

M01 · FY2005 · RR